Re-Sleeve Gastrectomy (Revisional Sleeve Gastrectomy)

Sleeve gastrectomy is the most commonly performed bariatric operation in the world, but weight regain or insufficient weight loss occurs in up to 30% of patients (Hany et al., Obesity Surgery, 2023). One reason is sleeve dilation: over time, the narrow gastric tube stretches and holds more food. Another is a retained fundus, where part of the upper stomach was left behind during the original operation. Either way, the sleeve loses the restriction that made it work.

Re-sleeve gastrectomy (ReSG) addresses that mechanical problem directly. The dilated portion of the stomach is resected again over a calibrating tube to recreate a narrow sleeve. The intestines are not rerouted, so there are no new connections, no malabsorption, and no change to how nutrients are absorbed beyond what the original sleeve did.

Patient selection is essential. Re-sleeve is appropriate only when imaging shows a dilated sleeve or retained fundus, typically a residual gastric volume greater than 250 mL on CT volumetry, and when significant reflux has been excluded (Antonopulos et al., Obesity Surgery, 2019; El Khoury et al., International Journal of Surgery, 2023). In a 2026 series of 101 patients from a high-volume U.S. center, re-sleeve produced a mean total weight loss of about 31% that held steady at 1, 2, and 3 years, with no deaths (Ma et al., Surgery for Obesity and Related Diseases, 2026).

It is also a more demanding operation than it looks. National data on more than 3,200 re-sleeves show serious complications in 5.13%, compared with 2.03% after a first-time sleeve. Re-sleeve was the strongest independent predictor of serious complications in that analysis (Kachornvitaya et al., Surgery for Obesity and Related Diseases, 2025). For many patients, especially those with reflux, a normal-sized sleeve, or diabetes, conversion to bypass or SADI-S is the better operation. Every pathway is compared on the Revisional Bariatric Surgery hub.

A sleeve gastrectomy works through restriction and hormonal change. Removing about 80% of the stomach reduces how much you can eat at once and lowers production of ghrelin, the main hunger hormone, which is made largely in the fundus. When the sleeve stretches or part of the fundus was left behind, both effects weaken: meals get larger, and hunger returns.

Re-sleeve gastrectomy removes the excess stomach again. That restores a narrow tube and takes out any remaining fundus. The operation works best when the problem is clearly anatomic, such as a dilated upper pouch, a retained fundus, or a globally enlarged sleeve (Coste et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2021).

Re-sleeve is purely restrictive. It does not add the malabsorptive or intestinal-hormone effects of a bypass or duodenal switch. Network meta-analysis shows that SADI-S produces among the largest additional weight loss after a failed sleeve, and that re-sleeve ranks best for safety among the surgical revisions (Małczak et al., Obesity Reviews, 2025). Choosing between them means weighing effectiveness against risk for your anatomy and health.

• Restores restriction without rerouting the intestines. There are no new anastomoses, no risk of marginal ulcer or internal hernia, and no added malabsorption.

• Meaningful, sustained weight loss in selected patients. Mean total weight loss was about 31% at 1, 2, and 3 years, and mean excess weight loss was about 62–64% (Ma et al., Surgery for Obesity and Related Diseases, 2026). A meta-analysis of 300 patients found a pooled excess weight loss of 61.5% (Aiolfi et al., Surgery for Obesity and Related Diseases, 2020).

• Corrects a technical problem. When a retained fundus or dilated pouch is the cause, re-sleeve fixes the underlying anatomy rather than adding a new operation on top of it.

• Short hospital stay. Mean length of stay was 1.7 days in a large U.S. series (Ma et al., Surgery for Obesity and Related Diseases, 2026).

• Keeps sleeve-specific advantages. The pylorus is preserved, dumping syndrome is uncommon, and the stomach remains accessible to standard endoscopy.

• Preserves future options. If needed later, a re-sleeved stomach can still be converted to gastric bypass, SADI-S, MagDI, or duodenal switch.

Re-sleeve gastrectomy may be appropriate for patients who have:

• Weight regain or insufficient weight loss after sleeve gastrectomy, commonly defined as excess weight loss below 50% (Antonopulos et al., Obesity Surgery, 2019).

• Documented sleeve dilation or a retained fundus on CT volumetry or barium swallow, generally a residual gastric volume above 250 mL. Some programs use a 350 mL threshold for global dilation (El Khoury et al., International Journal of Surgery, 2023; Coste et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2021).

• No significant gastroesophageal reflux disease (GERD), ideally confirmed by pH testing and upper endoscopy (Cornejo et al., Surgical Endoscopy, 2024).

• No Barrett's esophagus or erosive esophagitis. Both are generally treated as contraindications to re-sleeve (Antonopulos et al., Obesity Surgery, 2019).

• A completed nutritional, behavioral, and medical evaluation, including a review of eating patterns and anti-obesity medication options.

Who is usually better served by another operation:

• Reflux, erosive esophagitis, Barrett's esophagus, or a hiatal hernia with reflux. Conversion to gastric bypass is the most effective treatment for reflux after a sleeve, with 60–100% resolution of GERD symptoms (Vosburg et al., Surgery for Obesity and Related Diseases, 2026). See Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion and Gastric Bypass (Roux-en-Y) for GERD.

• A normal-sized sleeve (residual volume under 250 mL). Re-sleeving a sleeve that isn't dilated won't fix the problem. Bypass or a malabsorptive revision is preferred (Antonopulos et al., Obesity Surgery, 2019).

• Type 2 diabetes or a high BMI where maximum weight loss is the goal. Malabsorptive conversions produce significantly more weight loss than re-sleeve at 2 and 3 years (Dirnberger et al., Obesity Surgery, 2023). See Sleeve to SADI-S Conversion and Sleeve to MagDI Conversion.

Re-sleeve gastrectomy is performed laparoscopically or robotically under general anesthesia, usually through four to five small incisions.

The surgeon first releases adhesions from the original operation, separating the stomach from the liver and pancreas. The entire left side of the existing sleeve is then freed, starting below the first staple line from the original surgery. A calibrating tube (bougie), typically 36–40 French, is placed through the mouth into the stomach to guide the new size (Antonopulos et al., Obesity Surgery, 2019; Hany et al., Obesity Surgery, 2023).

The stomach is divided with surgical staplers, starting about 6 cm from the pylorus and working up toward the angle of His. All dilated stomach and any retained fundus are removed. When the dilation is limited to the upper pouch, only that segment may need to be re-stapled (Antonopulos et al., Obesity Surgery, 2019). Because re-stapling tissue that has already been stapled is the main source of leak risk, the surgeon pays close attention to staple height, tissue thickness, and the new staple line. Many surgeons reinforce or oversew the staple line, and a leak test is performed before closing (Antonopulos et al., Obesity Surgery, 2019).

Any hiatal hernia is repaired during the same operation, because an unrepaired hernia contributes to reflux after a sleeve (Hany et al., Obesity Surgery, 2023). See Hiatal Hernia Repair After Sleeve Gastrectomy. Mean operative time in a large U.S. series was about 97 minutes (Ma et al., Surgery for Obesity and Related Diseases, 2026).

Re-sleeve gastrectomy is safe in experienced hands but carries more risk than a first-time sleeve, because the surgeon is re-stapling scarred, previously divided stomach.

• Staple line leak. The most important risk of re-sleeve. In national registry data, the leak rate after re-sleeve was 1.3%, compared with 0.1% after a primary sleeve and 0.5% after sleeve-to-bypass conversion (Cornejo et al., Surgical Endoscopy, 2024). Single-center series have reported 5.9% (Ma et al., Surgery for Obesity and Related Diseases, 2026), and pooled analyses 2.0–3.6% (Aiolfi et al., Surgery for Obesity and Related Diseases, 2020; Franken et al., Obesity Surgery, 2022).

• Serious complications overall. 5.13% after re-sleeve vs 2.03% after a primary sleeve. Re-sleeve was independently associated with 2.26 times the odds of a serious complication. Mortality was low and similar between the two (Kachornvitaya et al., Surgery for Obesity and Related Diseases, 2025).

• Narrowing (stenosis). Gastric stenosis occurred in 5.1% of patients in one long-term series (El Khoury et al., International Journal of Surgery, 2023).

• Bleeding in about 2.5% (El Khoury et al., International Journal of Surgery, 2023).

• Readmission and reoperation. At 30 days, rates were 9.9% and 7.9% in a high-volume series (Ma et al., Surgery for Obesity and Related Diseases, 2026).

• New or worsening reflux. Use of reflux medication increased significantly after re-sleeve, even though symptoms were generally well controlled (Ma et al., Surgery for Obesity and Related Diseases, 2026).

• Wound infection. Revisional sleeve procedures carry about twice the odds of surgical site infection of primary sleeves (Bennett et al., Surgical Endoscopy, 2023).

• Blood clots, anesthesia risks, and the general risks of any abdominal operation.

Most patients stay in the hospital 1–2 days. Mean stay was 1.7 days in a large U.S. series (Ma et al., Surgery for Obesity and Related Diseases, 2026). Some programs obtain a contrast study before discharge to check the staple line.

Diet advances in stages, as it did after your first sleeve: clear liquids, then full liquids, then pureed foods, then soft foods, over about 4–6 weeks. Most patients return to desk work in 1–2 weeks and to physically demanding work in 4–6 weeks.

Warning signs that need immediate attention include fever, a rapid heart rate, worsening abdominal or left shoulder pain, persistent vomiting, or inability to keep liquids down. These can be early signs of a leak or narrowing.

The best evidence for re-sleeve covers 3 to 4 years. In the largest recent U.S. series, mean total weight loss was 31.0%, 30.3%, and 30.9% at 1, 2, and 3 years, so results were stable over that period (Ma et al., Surgery for Obesity and Related Diseases, 2026). In a series with a mean follow-up of about 45 months, mean BMI fell from 40.0 to 33.1 (El Khoury et al., International Journal of Surgery, 2023). Pooled data showed a BMI reduction of about 10.8 points beyond 4 years, although few patients were followed that long (Franken et al., Obesity Surgery, 2022).

Long-term data beyond 5 years are limited. Comparative studies suggest that malabsorptive conversions outperform re-sleeve over time, with the difference becoming significant at 2 and 3 years (Dirnberger et al., Obesity Surgery, 2023). Re-sleeve should be seen as one option within lifelong management of a chronic disease. If weight regain returns, anti-obesity medication or a later malabsorptive conversion is still available.

More in Sleeve Gastrectomy Revisions

Related procedures: Hiatal Hernia Repair After Sleeve Gastrectomy, Gastric Sleeve Stricture Management, Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion, Sleeve Gastrectomy to SADI-S Conversion, Sleeve Gastrectomy to Duodenal Switch Conversion, Sleeve to OAGB Conversion. Related primary operations: Sleeve Gastrectomy. For an overview of all options, see Revisional Bariatric Surgery.

Conditions treated: Weight Regain, Inadequate Weight Loss, Acid Reflux, Stomach Narrowing (Stricture) After Bariatric Surgery, Hiatal Hernia & Paraesophageal Hernia, Barrett’s Esophagus.

The most important decision in re-sleeve surgery is whether to do it at all. National registry data show that re-sleeve has twice the serious complication rate of a primary sleeve (Kachornvitaya et al., Surgery for Obesity and Related Diseases, 2025). It works only when imaging confirms a dilated sleeve and reflux has been excluded (Cornejo et al., Surgical Endoscopy, 2024). Making that call correctly takes a surgeon who performs every sleeve revision option, not just one.

Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified surgeon and a diplomate of the American Board of Obesity Medicine, so he treats obesity both medically and surgically. He served for 10 years as a fellowship program director, training surgeons in the bariatric and reoperative techniques these cases demand. Because his practice is also a foregut and antireflux surgery practice, reflux evaluation is not an afterthought. Upper endoscopy, pH testing when indicated, and assessment for hiatal hernia are part of every sleeve revision workup.

His program offers every post-sleeve option in one place:

• Re-sleeve gastrectomy

• Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion

• Sleeve to SADI-S Conversion

• Sleeve to MagDI Conversion

• Hiatal Hernia Repair After Sleeve Gastrectomy

• Anti-obesity medication

That range means your operation is chosen based on your sleeve volume, reflux status, diabetes, and goals, not on what a single surgeon happens to offer.

Dr. de la Cruz-Muñoz has been performing bariatric surgery for over 25 years and has completed more than 9,000 bariatric operations, a volume few surgeons reach.

In properly selected patients with a documented dilated sleeve, re-sleeve gastrectomy has produced:

• About 31% mean total weight loss, sustained through 3 years (Ma et al., Surgery for Obesity and Related Diseases, 2026).

• About 61–64% excess weight loss across a single-center series and a pooled meta-analysis (Ma et al., Surgery for Obesity and Related Diseases, 2026; Aiolfi et al., Surgery for Obesity and Related Diseases, 2020).

• An average BMI drop of about 7–10 points (El Khoury et al., International Journal of Surgery, 2023; Franken et al., Obesity Surgery, 2022).

Results depend heavily on how dilated the sleeve is. Patients with a large residual volume or a clearly retained fundus tend to benefit most. For patients who need the most additional weight loss, SADI-S produces significantly greater total weight loss than other sleeve revisions (Małczak et al., Obesity Reviews, 2025).

Re-sleeve gastrectomy can improve weight-related conditions such as high blood pressure, sleep apnea, joint pain, and blood sugar control, mainly through renewed weight loss (Hany et al., Obesity Surgery, 2023). However, metabolic outcome data specific to re-sleeve are limited, and most studies focus on weight loss and safety.

For patients whose main goal is diabetes remission, the evidence favors operations with an intestinal component. National analyses suggest that alternative revisions may offer more durable weight loss and better metabolic outcomes than re-sleeve (Kachornvitaya et al., Surgery for Obesity and Related Diseases, 2025). Patients with poorly controlled type 2 diabetes should discuss Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion, Sleeve to SADI-S Conversion, or Sleeve to MagDI Conversion.

A re-sleeve restores the tool, but lasting success depends on how it is used. The program includes:

• Structured dietitian follow-up focused on protein first, portion awareness, and avoiding grazing and high-calorie liquids, the habits most likely to stretch a sleeve again.

• Regular body composition monitoring to track fat loss and muscle preservation, not just weight.

• Early use of anti-obesity medication if weight loss plateaus or regain begins, rather than waiting for a large regain.

• Behavioral health support for emotional or binge eating.

• Annual visits for life, with labs and a weight review.

Reflux is the deciding factor in sleeve revision. The long-term incidence of GERD after sleeve gastrectomy is 20–30% (Vosburg et al., Surgery for Obesity and Related Diseases, 2026). Because a re-sleeve recreates a narrow, high-pressure tube, it can worsen existing reflux. In a 2026 U.S. series, reflux medication use increased significantly after re-sleeve, even though symptoms were generally controlled (Ma et al., Surgery for Obesity and Related Diseases, 2026).

For that reason:

• Every patient needs an upper endoscopy before re-sleeve, and pH testing is used whenever reflux is suspected (Cornejo et al., Surgical Endoscopy, 2024).

• Symptomatic GERD, erosive esophagitis, and Barrett's esophagus are contraindications to re-sleeve (Antonopulos et al., Obesity Surgery, 2019).

• Any hiatal hernia is repaired during the operation.

• Patients with reflux are best served by conversion to gastric bypass, which resolves GERD symptoms in 60–100% of patients (Vosburg et al., Surgery for Obesity and Related Diseases, 2026).

See GERD / Acid Reflux, Gastric Bypass (Roux-en-Y) for GERD, and Hiatal Hernia Repair After Sleeve Gastrectomy.

Re-sleeve is one of several options after a failed sleeve gastrectomy:

• Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion. The most common sleeve revision in the U.S., accounting for about 76% of revisions, compared with about 8% for re-sleeve (Cornejo et al., Surgical Endoscopy, 2024). It is the operation of choice when reflux is present.

• Sleeve to SADI-S Conversion. Produces the greatest additional weight loss in network meta-analysis (Małczak et al., Obesity Reviews, 2025).

• Sleeve to MagDI Conversion. A newer duodeno-ileal option that uses magnetic compression instead of a hand-sewn or stapled anastomosis.

• One-Anastomosis Gastric Bypass (OAGB/MGB). Superior to re-sleeve for excess weight loss in network analysis (Małczak et al., Obesity Reviews, 2025).

• Endoscopic revision ("sleeve-in-sleeve"). In a propensity-matched study, endoscopic revision produced weight loss at 12 months similar to surgical revision, with fewer serious adverse events (0% vs 11%) (Jirapinyo et al., Gastrointestinal Endoscopy, 2026). Longer-term data are still emerging. See Endoscopic Sleeve Gastroplasty (ESG).

• Anti-obesity medication, alone or combined with any of the above.

If weight regain recurs after re-sleeve, conversion to bypass, SADI-S, or MagDI remains possible. All options are compared on the Revisional Bariatric Surgery hub.

Every period of rapid weight loss puts muscle at risk, and many revision patients have already lost muscle after their first sleeve. Preserving lean body mass protects metabolism, strength, and long-term weight maintenance.

The program emphasizes:

• Meeting daily protein targets, at least 60 grams per day and individualized by your dietitian (Mechanick et al., Obesity, 2020).

• Resistance training at least 2 days per week once cleared by your surgeon.

• Body composition testing before surgery and during follow-up, so the team can track fat mass, muscle mass, and visceral fat rather than weight alone.

Coverage for revisional bariatric surgery varies widely by plan. In one survey of major insurers, only 67% of policies covered a second bariatric procedure for weight loss failure (Gebran et al., Obesity Surgery, 2020).

Most plans require:

• Documentation of the original sleeve (operative note).

• Evidence of weight regain or insufficient weight loss.

• Imaging showing sleeve dilation (CT volumetry or upper GI series).

• Upper endoscopy.

• Current BMI and comorbidity documentation.

• Nutritional and psychological evaluations.

Some plans also require a period of supervised weight management. The team helps assemble the documentation and submit the prior authorization.

• Upper endoscopy to evaluate for esophagitis, Barrett's esophagus, hiatal hernia, and sleeve shape.

• CT gastric volumetry and/or upper GI contrast study to measure the residual stomach and identify dilation or a retained fundus (Coste et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2021).

• pH testing when reflux symptoms or endoscopic findings suggest GERD.

• Nutritional labs, with correction of any deficiencies before surgery.

• Dietitian and behavioral health evaluations.

• Smoking and nicotine cessation, which is essential to reduce leak and ulcer risk.

• A pre-operative liquid diet, often 1–2 weeks, to shrink the liver.

• Medication review, including GLP-1 medications, blood thinners, and anti-inflammatories.

Nutrition after re-sleeve follows the same staged progression as a primary sleeve: liquids, then pureed, then soft, then regular textures over about 4–6 weeks.

• Protein first at every meal, with a target of at least 60 grams daily (Mechanick et al., Obesity, 2020).

• Small, slow meals. Stop at the first sign of fullness.

• Separate liquids from meals by about 30 minutes.

• At least 64 ounces of fluid daily, sipped throughout the day.

• Lifelong bariatric multivitamin, including zinc 8–11 mg and copper 1 mg.

Early walking begins immediately after surgery. Light activity continues through week 2. Resistance training typically begins at week 4–6.

A CT or upper GI study showing a dilated sleeve, done at home, lets the team confirm that re-sleeving is appropriate before you travel. The usual stay is approximately one week. Reflux symptoms are followed closely after surgery, including by telehealth.